ATE507827T1 - Behandlung pervasiver entwicklungsstörungen - Google Patents
Behandlung pervasiver entwicklungsstörungenInfo
- Publication number
- ATE507827T1 ATE507827T1 AT07858785T AT07858785T ATE507827T1 AT E507827 T1 ATE507827 T1 AT E507827T1 AT 07858785 T AT07858785 T AT 07858785T AT 07858785 T AT07858785 T AT 07858785T AT E507827 T1 ATE507827 T1 AT E507827T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- developmental disorders
- pervasive developmental
- protein
- source
- Prior art date
Links
- 208000012202 Pervasive developmental disease Diseases 0.000 title abstract 2
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000036353 Rett disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000000153 supplemental effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0624879.3A GB0624879D0 (en) | 2006-12-14 | 2006-12-14 | Treatment of pervasive development disorders |
| PCT/GB2007/004815 WO2008071991A1 (en) | 2006-12-14 | 2007-12-14 | Treatment of pervasive developmental disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507827T1 true ATE507827T1 (de) | 2011-05-15 |
Family
ID=37712065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07858785T ATE507827T1 (de) | 2006-12-14 | 2007-12-14 | Behandlung pervasiver entwicklungsstörungen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100055073A1 (enExample) |
| EP (1) | EP2091526B1 (enExample) |
| JP (1) | JP2010513259A (enExample) |
| AT (1) | ATE507827T1 (enExample) |
| AU (1) | AU2007331276A1 (enExample) |
| BR (1) | BRPI0720230B8 (enExample) |
| CA (1) | CA2672738A1 (enExample) |
| DE (1) | DE602007014400D1 (enExample) |
| ES (1) | ES2365469T3 (enExample) |
| GB (1) | GB0624879D0 (enExample) |
| IL (1) | IL199340A0 (enExample) |
| MX (1) | MX2009006459A (enExample) |
| PL (1) | PL2091526T3 (enExample) |
| RU (1) | RU2441652C2 (enExample) |
| WO (1) | WO2008071991A1 (enExample) |
| ZA (1) | ZA200904240B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010137944A1 (en) * | 2009-05-27 | 2010-12-02 | N.V. Nutricia | Treatment of hypercalcaemia |
| MX2013003636A (es) | 2013-03-27 | 2014-09-29 | Palsgaard Ind De Mexico S De R L De C V | Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad. |
| WO2015002527A1 (en) * | 2013-07-05 | 2015-01-08 | N.V. Nutricia | Amino acid composition for use in the treatment of a pdd |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US11617731B2 (en) | 2017-04-28 | 2023-04-04 | Axcella Health, Inc. | Amino acid compositions and their use for the treatment of traumatic brain injury |
| EP3630124A4 (en) * | 2017-05-24 | 2021-02-24 | Glycom A/S | Synthetic composition comprising oligosaccharides and its use in medical treatment. |
| MA49906A (fr) | 2017-08-14 | 2020-06-24 | Axcella Health Inc | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| WO2022258873A1 (es) * | 2021-06-09 | 2022-12-15 | Hospital Sant Joan De Deu | Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4414238A (en) * | 1981-12-24 | 1983-11-08 | Cutter Laboratories, Inc. | Liquid elemental diet |
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| SE510813C2 (sv) * | 1997-12-08 | 1999-06-28 | Arla Ekonomisk Foerening | Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen |
| WO2002043507A2 (en) * | 2000-11-30 | 2002-06-06 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| CN1255413C (zh) * | 2001-06-14 | 2006-05-10 | 阿克佐诺贝尔公司 | 作为ampa受体正性调节剂的(吡啶并/噻吩并)－[f]－氧杂吖庚因－5－酮衍生物 |
| US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
-
2006
- 2006-12-14 GB GBGB0624879.3A patent/GB0624879D0/en not_active Ceased
-
2007
- 2007-12-14 EP EP07858785A patent/EP2091526B1/en active Active
- 2007-12-14 PL PL07858785T patent/PL2091526T3/pl unknown
- 2007-12-14 MX MX2009006459A patent/MX2009006459A/es active IP Right Grant
- 2007-12-14 AT AT07858785T patent/ATE507827T1/de not_active IP Right Cessation
- 2007-12-14 WO PCT/GB2007/004815 patent/WO2008071991A1/en not_active Ceased
- 2007-12-14 BR BRPI0720230A patent/BRPI0720230B8/pt not_active IP Right Cessation
- 2007-12-14 RU RU2009126763/15A patent/RU2441652C2/ru active
- 2007-12-14 ZA ZA200904240A patent/ZA200904240B/xx unknown
- 2007-12-14 AU AU2007331276A patent/AU2007331276A1/en not_active Abandoned
- 2007-12-14 JP JP2009540868A patent/JP2010513259A/ja active Pending
- 2007-12-14 DE DE602007014400T patent/DE602007014400D1/de active Active
- 2007-12-14 ES ES07858785T patent/ES2365469T3/es active Active
- 2007-12-14 CA CA002672738A patent/CA2672738A1/en not_active Abandoned
-
2009
- 2009-06-12 US US12/483,580 patent/US20100055073A1/en not_active Abandoned
- 2009-06-14 IL IL199340A patent/IL199340A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009006459A (es) | 2009-11-23 |
| ES2365469T3 (es) | 2011-10-06 |
| EP2091526B1 (en) | 2011-05-04 |
| AU2007331276A2 (en) | 2011-03-31 |
| RU2441652C2 (ru) | 2012-02-10 |
| DE602007014400D1 (de) | 2011-06-16 |
| BRPI0720230B8 (pt) | 2021-05-25 |
| BRPI0720230A2 (pt) | 2013-12-24 |
| PL2091526T3 (pl) | 2011-10-31 |
| IL199340A0 (en) | 2010-03-28 |
| AU2007331276A1 (en) | 2008-06-19 |
| GB0624879D0 (en) | 2007-01-24 |
| CA2672738A1 (en) | 2008-06-19 |
| BRPI0720230B1 (pt) | 2020-12-15 |
| WO2008071991A1 (en) | 2008-06-19 |
| RU2009126763A (ru) | 2011-01-20 |
| EP2091526A1 (en) | 2009-08-26 |
| US20100055073A1 (en) | 2010-03-04 |
| JP2010513259A (ja) | 2010-04-30 |
| ZA200904240B (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE507827T1 (de) | Behandlung pervasiver entwicklungsstörungen | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| EA201170508A1 (ru) | Производные 1-амино-2-циклобутилэтилбороновой кислоты | |
| TW200637614A (en) | Bendamustine pharmaceutical compositions | |
| BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
| MA32539B1 (fr) | Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée | |
| EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
| ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
| NO20083780L (no) | Topisk sammensetning omfattende en antibakteriell substans | |
| EA200801551A1 (ru) | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
| DE602007006010D1 (de) | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| EA200802054A1 (ru) | Ингибиторы фермента | |
| EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| EA201000854A1 (ru) | Применение эдта и ее солей для профилактики и лечения дизентерии свиней и усиления эффектов антибиотиков, проявляющихся при этом заболевании | |
| MA35895B1 (fr) | Inhibiteurs d'iap | |
| EP2257161A4 (en) | AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | |
| UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |